Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 20 August 2025, Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today.

Webcast scheduled for 20 August 2025, at 09:00 (CET). Link to webcast here.

Second Quarter 2025 Business Update

Highlights

On track toward IND/CTA submission in 2H 2025 and first-in-human trial initiation in 1H 2026.

Broadened regulatory engagement: following positive FDA pre-IND feedback (Q2 2024), submitted a scientific advice briefing package to the UK MHRA in July 2025 for ZI-MA4-1.

Initiated GMP manufacturing of clinical material in July 2025, a major step in clinical readiness; scalable platform developed with Catalent can deliver hundreds of doses from a single batch.

Strong support from leading clinical experts and sites; refined trial design and moving to operational readiness ahead of IND/CTA submission

Financial highlights

Total operating expenses amounted to MNOK 38.4 in Q2 2025, and MNOK 67.8 YTD. Total loss was MNOK 37.5 for the period and MNOK 66.0 YTD.

Net negative cash flow from operations was MNOK 59.4 in Q2 2025, ...